Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Key Points
Key Points
- The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
- These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
- This guideline focuses on strategies for controlling the growth of these tumors.
Treatment
...atment
...Recommendations for G1–G3 GEP-NET...
Recommendation 1.1Selection of initial...
...tion 1.2All treatment decisions should be guid...
...1.3Patients should be assessed for SST...
...Therapy for Metastatic G1–G2 Gast...
...st-line Systemic Therapy for G1–G2...
...on 2.1SSAs (octreotide or lanreotide) a...
...n 2.2In the less common circumstance of pa...
...er-line Systemic Therapy for G1–G2 G...
...ecommendation 2.3Peptide receptor radionuc...
Recommendation 2.4Everolimus is recommended for...
...temic Therapy for Metastatic G1–G...
...Systemic Therapy for G1–G2 pa...
Recommendation 3.1SSAs (octreotide or la...
...ecommendation 3.2Chemotherapy (e.g., capecitabin...
...n 3.3Chemotherapy (e.g., CAPTEM), everolimus, or...
...cond- or Later-line Systemic Therapy...
....4PRRT for SSTR-positive tumors, chemothe...
...Systemic Therapy for G3 GEP-NET...
...on 4.1The range of systemic options o...
...WHO Classification and Grading Crite...
...stemic Therapy for Tumor Control i...
ASCO believes that cancer clinical trial...